July 8, 2020 / 12:35 PM / a month ago

BRIEF-Xencor And Atreca Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

July 8 (Reuters) - Atreca Inc:

* XENCOR AND ATRECA ENTER STRATEGIC COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC ANTIBODIES

* XENCOR INC - UNDER TERMS, CO, ATRECA WILL ENGAGE IN A THREE-YEAR DISCOVERY PROGRAM

* XENCOR - AGREEMENT ALLOWS EACH PARTNER TO PURSUE UPTO 2 PROGRAMS INDEPENDENTLY, WITH MID- TO HIGH-SINGLE DIGIT PERCENT ROYALTY PAYABLE ON NET SALES

* XENCOR - UNDER TERMS, ATRECA TO PROVIDE ANTIBODIES AGAINST NOVEL TUMOR TARGETS FROM WHICH XENCOR WILL ENGINEER XMAB BISPECIFIC ANTIBODIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below